Navigation Links
Auxilium Pharmaceuticals Reports Preliminary Fourth Quarter 2010 Net Revenue and Announces 2011 XIAFLEX Revenue Guidance
Date:1/10/2011

tion slides and the question and answer session webcast can be accessed via a link on the "For Investors" section of the Auxilium web site under the "Events" tab.  The replay will be available for ninety days after the event.

About AuxiliumAuxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company with a focus on developing and marketing products to predominantly specialist audiences, such as urologists, endocrinologists, certain targeted primary care physicians, hand surgeons, subsets of orthopedic, general, and plastic surgeons who focus on the hand, and rheumatologists.  Auxilium markets XIAFLEX® (collagenase clostridium histolyticum) for the treatment of adult Dupuytren's contracture patients with a palpable cord and Testim® 1%, a topical testosterone gel, for the treatment of hypogonadism.  Auxilium has four projects in clinical development.  XIAFLEX is in phase III of development for the treatment of Peyronie's disease and is in phase II of development for treatment of Frozen Shoulder syndrome (Adhesive Capsulitis).  Auxilium's transmucosal film product candidate for the treatment of overactive bladder (AA4010) and its fentanyl pain product using its transmucosal delivery system are in phase I of development.  The Company is currently seeking a partner to further develop these product candidates.  Auxilium has rights to additional pain products and products for hormone replacement and urologic disease using its transmucosal film delivery system.  Auxilium also has options to all indications using XIAFLEX for non-topical formulations.  For additional information, visit http://www.auxilium.com.

SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

This release contains "forward-looking-statements" within the meaning of The Private Securities Litigation Reform Act of 1995, including statements regarding the
'/>"/>

SOURCE Auxilium Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytrens Contracture
3. BioSpecifics Technologies Corp. Announces Auxilium XIAFLEX® Update
4. Auxilium Pharmaceuticals, Inc. Announces Initiation of XIAFLEX® Phase III Studies for Peyronies Disease
5. Auxilium Pharmaceuticals, Inc. Announces Issuance of Patent for Clostridial Collagenase
6. Auxilium Pharmaceuticals to Present at the 2010 Annual Credit Suisse Healthcare Conference
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
9. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
10. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
11. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... , August 31, 2015 ... BOLT, OTCQX: BLGTY) ("BioLight" or the "Company"), a ... innovations in ophthalmology and cancer diagnostics, today announced ... MCTC), has identified several new genetic markers with ... in patients treated with bisphosphonate drugs and was ...
(Date:8/31/2015)... PARK, Calif. , Aug. 31, 2015 /PRNewswire/ ... company focused on the emerging field of regenerative ... successfully dosed at Chicago -based ... clinical trial evaluating activity of escalating doses of ... with sensory and motor complete cervical spinal cord ...
(Date:8/31/2015)... , Aug. 31, 2015 Bionomics Limited ... and development of innovative therapeutics for the treatment of ... today announced that its BNC101 IND submission has passed ... Bionomics plans to initiate a Phase 1 clinical trial ... with metastatic pancreatic cancer prior to 31 December 2015. ...
Breaking Medicine Technology:BioLight Reports Positive Clinical Study Results for Identifying New Genetic Markers to Predict Risk of Developing BRONJ 2BioLight Reports Positive Clinical Study Results for Identifying New Genetic Markers to Predict Risk of Developing BRONJ 3BioLight Reports Positive Clinical Study Results for Identifying New Genetic Markers to Predict Risk of Developing BRONJ 4Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 4Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 5Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 6Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 2Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 3Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 4
... Inspiration Biopharmaceuticals, Inc. (Inspiration) today announced data from ... recombinant porcine factor VIII product (rpFVIII), intended for the ... inhibitors and in people with acquired hemophilia.  The data ... with the 23rd Congress of the International Society on ...
... Varian Medical Systems (NYSE: VAR ) has ... to hospitals in Scotland as part of a major nationwide ... accelerators, ancillary equipment and software from Varian, the world leader ... ageing treatment machines at radiotherapy departments in Glasgow, Edinburgh, Dundee, ...
Cached Medicine Technology:Inspiration Biopharmaceuticals Announces Data from OBI-1 Pivotal-Stage Program in Hemophilia at 23rd ISTH Congress 2Inspiration Biopharmaceuticals Announces Data from OBI-1 Pivotal-Stage Program in Hemophilia at 23rd ISTH Congress 3Inspiration Biopharmaceuticals Announces Data from OBI-1 Pivotal-Stage Program in Hemophilia at 23rd ISTH Congress 4Inspiration Biopharmaceuticals Announces Data from OBI-1 Pivotal-Stage Program in Hemophilia at 23rd ISTH Congress 5Scottish Executive Awards Varian Medical Systems Major Contract to Supply Advanced Radiotherapy Equipment to Scotland's Five Cancer Centers 2Scottish Executive Awards Varian Medical Systems Major Contract to Supply Advanced Radiotherapy Equipment to Scotland's Five Cancer Centers 3
(Date:8/31/2015)... ... August 31, 2015 , ... Kognito ... and assess their competencies in managing challenging conversations, announced today that Glenn Albright, ... Defense Centers of Excellence for Psychological Health and Traumatic Brain Injury (DCoE) Summit ...
(Date:8/31/2015)... ... August 31, 2015 , ... The Foundation for ... the facts about the role of heredity in below-the-belt gynecologic cancers. , ... Angelina Jolie Pitt’s decisions to have both her breasts and ovaries removed to ...
(Date:8/31/2015)... ... , ... “My mother and husband use oxygen therapy and the tubing irritates ... could be a comfortable way to prevent the irritation, so I invented this.” She ... more secure way to anchor the cannula tubing used in oxygen therapy and it ...
(Date:8/31/2015)... , ... August 31, 2015 , ... For 12 years, ... have acknowledged September 26th as Mesothelioma Awareness Day . On this day, and ... with several ways of becoming involved and helping the cause. , “One of the ...
(Date:8/31/2015)... ... August 31, 2015 , ... Westchester Insurance, ... Prairie, is teaming up with the Tarrant County chapter of Meals on Wheels ... Wheels is the oldest and largest national organization that supports the more than ...
Breaking Medicine News(10 mins):Health News:Kognito’s Glenn Albright to Present at DCoE Summit 2Health News:Foundation for Women’s Cancer Alerts Women to the Facts About the Role of Heredity in Gynecologic Cancers 2Health News:Foundation for Women’s Cancer Alerts Women to the Facts About the Role of Heredity in Gynecologic Cancers 3Health News:Foundation for Women’s Cancer Alerts Women to the Facts About the Role of Heredity in Gynecologic Cancers 4Health News:InventHelp® Inventor Designs Nasal Cannula Ear Protector (AVZ-1217) 2Health News:Cancer Research Organization Paints the World in Mesothelioma Awareness 2Health News:Cancer Research Organization Paints the World in Mesothelioma Awareness 3Health News:Westchester Insurance and the Meals on Wheels Association Announce Joint Charity Effort to Provide Nutritious Meals for Senior Citizens 2Health News:Westchester Insurance and the Meals on Wheels Association Announce Joint Charity Effort to Provide Nutritious Meals for Senior Citizens 3
... double by waiting even a day after discharge, study finds ... people who have stents implanted to keep an artery open ... Plavix immediately, and that ignorance nearly doubles their risk for ... study, which involved 7,402 people who had the thin tubes ...
... processed foods account for nearly 16% of daily intake, ... The added sugars in prepared and processed foods are ... cholesterol, raising levels of potentially dangerous triglcerides and possibly ... looked at a group of people representative of the ...
... D.C. Levels of epidermal growth factor receptor (EGFR) may ... prior to their breast cancer diagnosis, according to findings presented ... 2010, held here April 17-21. The goal of the ... of the Epidemiology Program at the Fred Hutchinson Cancer Research ...
... that when a thin person is seen laying down ... see an overweight person relaxing, it,s automatically assumed they,re ... of A,s Faculty of Physical Education and Recreation, says ... Berry says just because a person is overweight, it ...
... ... Administration (FDA) approved an Investigational New Drug (IND) for a clinical trial for ischemic ... ... April 20, 2010 -- Stemedica Cell Technologies, Inc. (Stemedica), a world leader ...
... computer games helped in any way , TUESDAY, April ... reports that popular brain-training computer games do not improve ... conducted by the Medical Research Council (MRC) in collaboration ... these brain games do little to boost the ability ...
Cached Medicine News:Health News:Many Don't Take Blood Thinner After Getting Stents 2Health News:Many Don't Take Blood Thinner After Getting Stents 3Health News:Added Sugars in Diet Threaten Heart Health 2Health News:Added Sugars in Diet Threaten Heart Health 3Health News:Increased EGFR levels may be an early marker of breast cancer 2Health News:FDA Approves Stemedica IND for Ischemic Stroke Clinical Trial 2Health News:'Brain Games' Do Not Make You Smarter 2Health News:'Brain Games' Do Not Make You Smarter 3